Qianyuan Pharmacy: Subsidiary granted approval for listing of Ibrutinib chemical raw materials.

Qianyuan Pharmaceuticals announced that its subsidiary, Jiangsu Jiayi Pharmaceutical Co., Ltd., has received the approval notification for the market application of the chemical raw material drug Ebastine issued by the National Medical Products Administration. Ebastine is used for symptomatic treatment of allergic rhinitis with or without allergic conjunctivitis, as well as chronic idiopathic urticaria. Ebastine was originally developed by INDUSTRIAS FARMACEUTICAS ALMIRALL, S.A., and the Ebastine tablets of its subsidiary, Hangzhou Qianyuan Baoling Pharmaceutical Co., Ltd., have passed consistency evaluation and are included in the national medical insurance catalog category B. After the approval of Ebastine raw materials for market launch, it will further reduce the production cost of formulation products and enhance the market competitiveness of the products.